망막정맥폐쇄증 치료 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측, 질환 유형별, 치료별, 최종사용자별, 지역별 부문, 경쟁(2020-2030년)

Retinal Vein Occlusion Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Disease Type, By Treatment, By End-user Region and Competition, 2020-2030F

US $ 4,500 ￦ 6,385,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500 ￦ 7,805,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000 ￦ 11,352,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

한글목차

망막정맥폐쇄증 치료 세계 시장 규모는 2024년 28억 7,000만 달러로 평가되었고, 예측 기간 동안 6.80%의 연평균 복합 성장률(CAGR)로 2030년에는 42억 6,000만 달러에 달할 것으로 예상됩니다.

세계 망막정맥폐쇄증 치료 시장은 광범위한 헬스케어 산업에서 역동적이고 빠르게 발전하고 있는 분야입니다. 망막정맥폐쇄증(RVO)은 흔한 안구 혈관 질환으로, 방치할 경우 시력 장애를 초래할 수 있어 환자와 의료진 모두에게 중요한 관심사가 되고 있습니다. 전 세계적으로 고령화가 진행됨에 따라 RVO의 유병률은 증가하고 있으며, 혁신적이고 효과적인 치료 옵션에 대한 수요가 증가하고 있습니다.

시장 개요
예측 기간	2026-2030년
시장 규모 : 2024년	28억 7,000만 달러
시장 규모 : 2030년	42억 6,000만 달러
CAGR : 2025-2030년	6.80%
급성장 부문	망막정맥 분지폐쇄증
최대 시장	북미

세계 RVO 치료 시장에 영향을 미치는 주요 요인으로는 의료 기술의 발전, 환자 인식 증가, 연구개발 활동의 활성화 등을 들 수 있습니다. 제약회사들은 환자의 예후와 삶의 질 향상에 초점을 맞추어 RVO에 대응하기 위한 신약 및 치료법 개발에 적극 나서고 있으며, RVO 치료 시장에는 약리학적 중재, 레이저 치료, 수술 등 다양한 접근법이 있습니다. 항VEGF(혈관내피성장인자) 약물은 RVO 환자의 부종 감소와 시력 개선에 도움이 되는 효과적인 약리학적 치료 옵션으로 최근 각광을 받고 있습니다. 또한, 합병증을 관리하고 망막 정맥의 혈류를 회복시키기 위해 레이저 치료와 수술적 개입도 일부 환자에서 시행되고 있습니다.

주요 시장 성장 촉진요인

고령화 인구 증가

주요 시장 이슈

제한된 치료 옵션

주요 시장 동향

약리학적 치료의 발전

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 세계의 망막정맥폐쇄증 치료 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 질환 유형별(망막중심정맥폐쇄증(CRVO), 망막정맥분지폐쇄 증(BRVO))
  • 치료별(항혈관내피세포성장인자(항VEGF), 코르티코스테로이드제, 기타)
  • 최종사용자별(병원 및 진료소, 약국 소매, 기타)
  • 지역별
  • 기업별(2024년)
• 시장 맵
  • 질환 유형별
  • 치료별
  • 최종사용자별
  • 지역별

제5장 아시아태평양의 망막정맥폐쇄증 치료 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 질환 유형별
  • 치료별
  • 최종사용자별
  • 국가별
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 호주
  • 일본
  • 한국

제6장 유럽의 망막정맥폐쇄증 치료 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 독일
  • 스페인
  • 이탈리아
  • 영국

제7장 북미의 망막정맥폐쇄증 치료 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 멕시코
  • 캐나다

제8장 남미의 망막정맥폐쇄증 치료 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 아르헨티나
  • 콜롬비아

제9장 중동 및 아프리카의 망막정맥폐쇄증 치료 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 사우디아라비아
  • 아랍에미리트(UAE)

제10장 시장 역학

• 성장 촉진요인
• 과제

제11장 시장 동향과 발전

• 최근 동향
• 제품 출시
• 인수합병(M&A)

제12장 세계의 망막정맥폐쇄증 치료 시장 : SWOT 분석

제13장 Porter의 Five Forces 분석

• 업계내 경쟁
• 신규 참여 가능성
• 공급업체의 힘
• 고객의 힘
• 대체품의 위협

제14장 경쟁 구도

• AbbVie Inc.
• F. Hoffmann-La Roche Ltd.
• Regeneron Pharmaceuticals Inc.
• Taiwan Liposome Company, Ltd.
• Aerie Pharmaceuticals Inc.
• CalciMedica Inc.
• Outlook Therapeutics, Inc.
• Kodiak Sciences Inc.
• Chugai Pharmaceutical Co., Ltd.
• Pfizer Inc.

제15장 전략적 제안

제16장 리서치사에 대해 & 면책사항

LSH

영문 목차

영문목차

Global Retinal Vein Occlusion Treatment Market was valued at USD 2.87 billion in 2024 and is expected to reach USD 4.26 billion by 2030 with a CAGR of 6.80% during the forecast period. The global retinal vein occlusion treatment market is a dynamic and rapidly evolving sector within the broader healthcare industry. Retinal vein occlusion (RVO) is a common vascular disorder of the eye that can lead to vision impairment if left untreated, making it a significant concern for both patients and healthcare professionals. As the aging population continues to grow worldwide, the prevalence of RVO is on the rise, driving the demand for innovative and effective treatment options.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 2.87 Billion
Market Size 2030	USD 4.26 Billion
CAGR 2025-2030	6.80%
Fastest Growing Segment	Branch Retinal Vein Occlusion
Largest Market	North America

Key factors influencing the global RVO treatment market include advancements in medical technology, increasing awareness among patients, and a surge in research and development activities. Pharmaceutical companies are actively engaged in the development of novel drugs and therapies to address RVO, with a focus on improving patient outcomes and quality of life. The market for RVO treatment encompasses various approaches, including pharmacological interventions, laser therapy, and surgical procedures. Anti-VEGF (vascular endothelial growth factor) drugs have gained prominence in recent years as an effective pharmacological treatment option, helping to reduce edema and improve vision in RVO patients. Additionally, laser therapy and surgical interventions are utilized in specific cases to manage complications or restore blood flow in the affected retinal veins.

Key Market Drivers

Growing Aging Population

The aging population is a significant factor contributing to the growth of the global retinal vein occlusion (RVO) treatment market. As the world's demographic landscape undergoes a profound shift, with a substantial increase in the elderly population, the incidence of age-related eye conditions, such as RVO, is on the rise. RVO is notably more prevalent in individuals over the age of 50, making it a condition closely associated with the aging process. This demographic shift is driving demand for effective RVO treatments and significantly impacting the market in several ways.

According to WHO, by 2030, 1 in 6 people in the world will be aged 60 years or over. At this time the share of the population aged 60 years and over will increase from 1 billion in 2020 to 1.4 billion. By 2050, the world's population of people aged 60 years and older will double (2.1 billion). The number of persons aged 80 years or older is expected to triple between 2020 and 2050 to reach 426 million.

Key Market Challenges

Limited Treatment Options

The global retinal vein occlusion (RVO) treatment market faces a significant hurdle in the form of limited treatment options, which is hindering its growth and effectiveness. RVO is a vascular eye disorder that can result in vision impairment, and while there have been notable advances in treatment options, there remains a substantial portion of patients for whom the available treatments may be insufficient. This limitation poses a major challenge, as it leaves a significant portion of RVO patients without optimal solutions for their condition.

At present, the primary pharmacological approach to RVO treatment involves anti-vascular endothelial growth factor (anti-VEGF) drugs, which have shown efficacy in addressing macular edema and inflammation. However, these treatments are not universally effective, and there is a considerable variation in patient responses. Some individuals may experience minimal or no improvement, while others may require ongoing treatment that can be burdensome and uncomfortable. The inability to offer personalized, effective treatment options for all RVO patients hinders the market's ability to meet the diverse needs of

Key Market Trends

Advancements in Pharmacological Treatments

Advancements in pharmacological treatments have played a pivotal role in boosting the global retinal vein occlusion (RVO) treatment market. RVO, a vascular eye disorder that can lead to vision impairment, has seen remarkable progress in the development of novel therapies, particularly in the form of anti-vascular endothelial growth factor (anti-VEGF) drugs. These advancements have significantly improved the landscape of RVO treatment, offering patients more effective and convenient options for managing the condition.

Anti-VEGF drugs, such as aflibercept and ranibizumab, have emerged as the cornerstone of RVO treatment, primarily addressing RVO-related macular edema. These drugs work by inhibiting the growth of abnormal blood vessels in the retina, reducing inflammation, and preventing the leakage of fluid into the macula. The introduction of anti-VEGF treatments has revolutionized RVO management, offering patients a less invasive and more patient-friendly therapeutic approach. They have proven effective in reducing edema, improving visual outcomes, and preserving the patient's quality of life.

Key Market Players

• AbbVie Inc.
• F. Hoffmann-La Roche Ltd.
• Regeneron Pharmaceuticals Inc.
• Taiwan Liposome Company, Ltd.
• Aerie Pharmaceuticals Inc.
• CalciMedica Inc.
• Outlook Therapeutics, Inc.
• Kodiak Sciences Inc.
• Chugai Pharmaceutical Co., Ltd.
• Pfizer Inc.

Report Scope:

In this report, the Global Retinal Vein Occlusion Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Retinal Vein Occlusion Treatment Market, By Disease Type:

• Central Retinal Vein Occlusion (CRVO)
• Branch Retinal Vein Occlusion (BRVO)

Retinal Vein Occlusion Treatment Market, By Treatment:

• Anti-vascular Endothelial Growth Factor (Anti-VEGF)
• Corticosteroid Drugs
• Others

Retinal Vein Occlusion Treatment Market, By End-user:

• Fully Automated
• Semi-Automated
• Manual

Retinal Vein Occlusion Treatment Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Retinal Vein Occlusion Treatment Market.

Available Customizations:

Global Retinal Vein Occlusion Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Retinal Vein Occlusion Treatment Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Disease Type (Central Retinal Vein Occlusion (CRVO), Branch Retinal Vein Occlusion (BRVO))
  • 4.2.2. By Treatment (Anti-vascular Endothelial Growth Factor (Anti-VEGF), Corticosteroid Drugs, Others)
  • 4.2.3. By End-user (Hospital & Clinics, Retail Pharmacy, Others)
  • 4.2.4. By Region
  • 4.2.5. By Company (2024)
• 4.3. Market Map
  • 4.3.1. By Disease Type
  • 4.3.2. By Treatment
  • 4.3.3. By End-user
  • 4.3.4. By Region

5. Asia Pacific Retinal Vein Occlusion Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Disease Type
  • 5.2.2. By Treatment
  • 5.2.3. By End-user
  • 5.2.4. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Retinal Vein Occlusion Treatment Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Disease Type
      • 5.3.1.2.2. By Treatment
      • 5.3.1.2.3. By End-user
  • 5.3.2. India Retinal Vein Occlusion Treatment Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Disease Type
      • 5.3.2.2.2. By Treatment
      • 5.3.2.2.3. By End-user
  • 5.3.3. Australia Retinal Vein Occlusion Treatment Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Disease Type
      • 5.3.3.2.2. By Treatment
      • 5.3.3.2.3. By End-user
  • 5.3.4. Japan Retinal Vein Occlusion Treatment Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Disease Type
      • 5.3.4.2.2. By Treatment
      • 5.3.4.2.3. By End-user
  • 5.3.5. South Korea Retinal Vein Occlusion Treatment Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Disease Type
      • 5.3.5.2.2. By Treatment
      • 5.3.5.2.3. By End-user

6. Europe Retinal Vein Occlusion Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Disease Type
  • 6.2.2. By Treatment
  • 6.2.3. By End-user
  • 6.2.4. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Retinal Vein Occlusion Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Disease Type
      • 6.3.1.2.2. By Treatment
      • 6.3.1.2.3. By End-user
  • 6.3.2. Germany Retinal Vein Occlusion Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Disease Type
      • 6.3.2.2.2. By Treatment
      • 6.3.2.2.3. By End-user
  • 6.3.3. Spain Retinal Vein Occlusion Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Disease Type
      • 6.3.3.2.2. By Treatment
      • 6.3.3.2.3. By End-user
  • 6.3.4. Italy Retinal Vein Occlusion Treatment Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Disease Type
      • 6.3.4.2.2. By Treatment
      • 6.3.4.2.3. By End-user
  • 6.3.5. United Kingdom Retinal Vein Occlusion Treatment Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Disease Type
      • 6.3.5.2.2. By Treatment
      • 6.3.5.2.3. By End-user

7. North America Retinal Vein Occlusion Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Disease Type
  • 7.2.2. By Treatment
  • 7.2.3. By End-user
  • 7.2.4. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Retinal Vein Occlusion Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Disease Type
      • 7.3.1.2.2. By Treatment
      • 7.3.1.2.3. By End-user
  • 7.3.2. Mexico Retinal Vein Occlusion Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Disease Type
      • 7.3.2.2.2. By Treatment
      • 7.3.2.2.3. By End-user
  • 7.3.3. Canada Retinal Vein Occlusion Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Disease Type
      • 7.3.3.2.2. By Treatment
      • 7.3.3.2.3. By End-user

8. South America Retinal Vein Occlusion Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Disease Type
  • 8.2.2. By Treatment
  • 8.2.3. By End-user
  • 8.2.4. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Retinal Vein Occlusion Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Disease Type
      • 8.3.1.2.2. By Treatment
      • 8.3.1.2.3. By End-user
  • 8.3.2. Argentina Retinal Vein Occlusion Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Disease Type
      • 8.3.2.2.2. By Treatment
      • 8.3.2.2.3. By End-user
  • 8.3.3. Colombia Retinal Vein Occlusion Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Disease Type
      • 8.3.3.2.2. By Treatment
      • 8.3.3.2.3. By End-user

9. Middle East and Africa Retinal Vein Occlusion Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Disease Type
  • 9.2.2. By Treatment
  • 9.2.3. By End-user
  • 9.2.4. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Retinal Vein Occlusion Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Disease Type
      • 9.3.1.2.2. By Treatment
      • 9.3.1.2.3. By End-user
  • 9.3.2. Saudi Arabia Retinal Vein Occlusion Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Disease Type
      • 9.3.2.2.2. By Treatment
      • 9.3.2.2.3. By End-user
  • 9.3.3. UAE Retinal Vein Occlusion Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Disease Type
      • 9.3.3.2.2. By Treatment
      • 9.3.3.2.3. By End-user

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Retinal Vein Occlusion Treatment Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. AbbVie Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Current Capacity Analysis
  • 14.1.5. Financials (In case of listed)
  • 14.1.6. Recent Developments
  • 14.1.7. SWOT Analysis
• 14.2. F. Hoffmann-La Roche Ltd.
• 14.3. Regeneron Pharmaceuticals Inc.
• 14.4. Taiwan Liposome Company, Ltd.
• 14.5. Aerie Pharmaceuticals Inc.
• 14.6. CalciMedica Inc.
• 14.7. Outlook Therapeutics, Inc.
• 14.8. Kodiak Sciences Inc.
• 14.9. Chugai Pharmaceutical Co., Ltd.
• 14.10.Pfizer Inc.

15. Strategic Recommendations

16. About Us & Disclaimer

관련자료